PhytoHealth Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2001
NCT01696565
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PhytoHealth Corporation | Yaoh-Shiang Lin

Active Ingredients

Drugs in Phase 4 Trials (1)

astragalus membranaceus (11 trials)

Drugs in Phase 3 Trials (2)

diclofenac (voltaren) (1 trial)

nalbuphine (nubain) (1 trial)

Drugs in Phase 2 Trials (7)

cisplatin (platinol) (1 trial)

leucovorin (1 trial)

pdc-748 (1 trial)

ph3 (2 trials)

phn121 (1 trial)

tegafur (1 trial)

uracil (1 trial)

Drugs in Phase 1 Trials (1)

phencynonate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cough (Phase 2)

Diabetic Nephropathies (Phase 2)

Esophageal Neoplasms (Phase 2)

Fatigue (Phase 4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Intracranial Hemorrhages (Phase 1)

Kidney Diseases (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neutropenia (Phase 2)

Osteoporosis (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Recurrence (Phase 2)

Stroke (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 11